Lastacaft®
alcaftadine 0.25% · ophthalmic solution
Allergy
Approved uses
Allergic conjunctivitis, prevention of itching
1 drop in each eye QD
Itch relief begins within 3 minutes and lasts at least 16 hours.
OFF-LABELNot in the FDA label for this product
Active mild to moderate allergic conjunctivitis, treatment rather than prevention
1 drop QD x 14 days
RCT · n=180 · single-site
Randomized observer-masked single-center trial (N=180, 60 per arm): mean total ocular symptom score fell from 7.7 at baseline to 0.2 at day 14 with alcaftadine, versus 0.4 with olopatadine 0.2% and 0.1 with bepotastine 1.5% (day 14 ANOVA P=0.0008); absolute separation between the three actives was small. Contact lens wearers and severe allergic conjunctivitis were excluded.
Contraindications
Hypersensitivity to any component of the product.
Ophthalmic solution, 3 mL fill in 5 mL bottle, 0.25% (2.5 mg/mL)
H1 histamine receptor antagonist and inhibitor of histamine release from mast cells. Decreased chemotaxis and inhibition of eosinophil activation have also been demonstrated.
Warnings & Precautions
- Contact lens wear: Remove contact lenses prior to instillation, and LASTACAFT should not be instilled while wearing contact lenses; the preservative benzalkonium chloride may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration.
- Contact lens-related irritation: LASTACAFT should not be used to treat contact lens-related irritation, and patients should be advised not to wear a contact lens if their eye is red.
- Eye injury and contamination: Care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle, to minimize eye injury and contamination of the dropper tip and solution. Keep bottle tightly closed when not in use.
Common Side Effects
The most frequent ocular adverse reactions, occurring in less than 4% of eyes treated, were eye irritation, burning or stinging upon instillation, eye redness, and eye pruritus. The most frequent non-ocular adverse reactions, occurring in less than 3% of subjects, were nasopharyngitis and headache. Postmarketing reports include eye discharge, eye swelling, erythema of eyelid, eyelid edema, increased lacrimation, blurred vision, hypersensitivity reactions including swelling of the face or allergic dermatitis, and somnolence.
Pregnancy: No adequate and well-controlled studies in pregnant women and limited human data. Oral dosing through organogenesis in rats and rabbits produced no maternal or embryofetal toxicity at clinically relevant doses; advise pregnant women of a potential risk to the fetus and mother, and use only if the potential benefit justifies the potential risk to fetus and mother.
Lactation: No information on presence in human milk, effects on the breastfed infant, or effects on milk production. The developmental and health benefits of breastfeeding should be considered, along with the mother's clinical need for LASTACAFT and any potential adverse effects on the breastfed infant.
Safety and effectiveness below age 2 not established.